Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release.

Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal

Avinger

Cepton

Crown ElectroKinetics

Penny stocks to buy for under $1 but are they worth the risk this week? The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 4 Under $1 To Watch This Week

BlackBerry

EVgo

Array Technologies

Cadence Design Systems

General Motors

Charles Schwab

Sooner or later, investors will stop fearing the “phantom recession,” i.e. the recession that really doesn't exist except in many economists' imaginations.

7 Growth Stocks With Huge Return Potential for Long-Term Investors

Aclarion Inc

Aeglea BioTherapeutics

Astra Space

Credit Suisse

Getaround Inc

Canoo

Inpixon

Tempo Automation Holdings Inc

VirnetX

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1

Appreciate Holdings Inc

How to use technology to trade penny stocks right now The post Using Technology to Trade Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Using Technology to Trade Penny Stocks in 2023

Bionano says it expects another quarter of revenue growth. The company makes genomic testing equipment.

Why Shares of Bionano Genomics Are Up Monday

Penny stocks to watch under $1 this week. The post Penny Stocks to Buy Now?

Penny Stocks to Buy Now? 7 Under $1 To Watch This Week

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain unaudited preliminary financial results and business updates for the first quarter ended March 31, 2023.

UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates

PNC Financial Services

XPeng

FANUC Corp

Interactive Brokers

MarketAxess Holdings

SolarEdge Technologies

There are multiple signs that inflation is rolling over, while consumer spending remains strong and corporate earnings are beating expectations. Meanwhile, the so-called credit crunch many investors have feared really isn't materializing.

7 Stocks That Could Skyrocket in the Next 12 Months

SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2023 with a broad range of content covering the utility of optical genome mapping (OGM) utility for cell bioprocessing quality control, solid tumor and hematological malignancy cancer research. AACR's annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine. The AACR conference will be held April 14-18, 2023, in Orlando, Florida.

Bionano Announces Presentation of OGM Utility Across Cancer Genomics Research Applications at the American Association for Cancer Research (AACR) Annual Meeting

Today, we circle back on an interesting diagnostic concern called Bionano Genomics, Inc. The company continues to build out its promising optical genome mapping capabilities.  However, Bionano is also bleeding cash.

Bionano Genomics: Dilution Coming

Plug Power

Tesla

A difficult year for the stock market hasn't made Wall Street any less optimistic about equities. According to various analysts and pundits, three high-growth stocks have the necessary tailwinds to catapult higher by as much as 741%.

3 Supercharged Growth Stocks With 662% to 741% Upside, According to Wall Street

VAALCO Energy

SoundHound AI Inc

A tried-and-true strategy for finding stocks to buy is to look in sectors of the economy that are growing or likely to. Although penny stocks carry more risk than higher-priced (and more well known) stocks, investors can use the same strategy to identify the most promising penny stocks.

The 3 Most Promising Penny Stocks to Buy in April

Successful growth stocks don't stay under the market's radar for long. Bionano is getting the buy-in it needs from researchers and academic groups.

Buy This Magnificent Growth Stock Before It's Too Late

SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Meeting 2023 with a broad range of content covering optical genome mapping's (OGM) utility for research areas including rare genetic disease and constitutional disorders. ACMG's Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research. The ACMG conference will be held March 14-18, 2023, in Salt Lake City, Utah.

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Featuring OGM Utility Across a Broad Range of Research Applications

SVB Financial Group

Shares of Bionano Genomics Inc. BNGO, -4.00% fell 0.8% in premarket trading Monday, after the life sciences instrumentation company said it had about $2.1 million in accounts with SIVB Financial Group's SIVB, -60.41% Silicon Valley Bank, which was closed by regulators last week. That exposure represented about 41% of the $5.1 million the company had in cash and cash equivalents as of Dec. 31.

Bionano Genomics' cash in SVB accounts represented about 41% of its cash and cash equivalents at yearend

Bionano Genomics, Inc. (NASDAQ: BNGO) illustrates the risk and reward involved with many penny stocks. And that relationship is highlighted further with companies that are involved in emerging sectors like optical gene mapping.

Is Bionano Genomics a Risk Worth Taking at This Price?

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Sung Ji Nam - Scotiabank Michael Okunewitch - Maxim Group Mark Massaro - BTIG Operator Good day and welcome to the Bionano Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please be advised that this conference is being recorded.

Bionano Genomics, Inc. (BNGO) Q4 2022 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates

Bionano Genomics is rapidly rolling out its genome mapping device. Its competitors don't have any product that serves the same purpose.

Is Bionano Genomics Stock a Buy Now?

Bionano Genomics, Inc. (NASDAQ:BNGO ) Cowen 43rd Annual Healthcare Conference March 6, 2023 1:30 PM ET Company Participants Erik Holmlin - Chief Executive Officer Conference Call Participants Tom Stevens - Life Science Tools & Diagnostic Team here at Cowen Tom Stevens All right, so should we get started?. So I'm Tom Stevens, Life Science Tools & Diagnostic Team here at Cowen.

Bionano Genomics, Inc. (BNGO) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)

With no recent stumbles and more growth on the way, buying shares now could be a smart move.

This Growth Stock Is Down 38% and Wall Street Says It's Worth Buying Hand Over Fist

Arrival Group

Caterpillar

PayPal

TripAdvisor

Volkswagen AG

Despite the “hotter-than-expected” U.S. inflation data reported on Feb. 24, the fundamentals of the U.S. economy remain pretty strong. But don't take my word for it; listen to the CEO of JPMorgan, Jamie Dimon, who told CNBC on Feb. 23 that “The U.S. economy is doing quite well.

7 Stocks to Buy on Weakness While You Can

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Bionano Genomics, Inc. (BNGO) to Report a Decline in Earnings: What to Look Out for

Inmode Ltd

Both have growth catalysts on the way, and plenty of recurring revenue too.

Get Ready to Soar: 2 High-Octane Growth Stocks Wall Street Expects to Climb in 2023

News for Bionano Genomics Stock (BNGO)